MapLight Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Dec 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Dec 4, 2025
MPLT$7.28+5.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $64,146 | $38,253 |
| Short-term investments | 163,022 | 70,542 |
| Prepaid expenses and other current assets | 18,138 | 5,807 |
| Total current assets | 245,306 | 114,602 |
| Property and equipment, net | 859 | 1,207 |
| Long-term investments | — | 11,380 |
| Restricted cash | 207 | 207 |
| Right of use asset | 5,710 | 6,354 |
| Other assets | 5,140 | 3,166 |
| Total assets | $257,222 | $136,916 |
| Liabilities, redeemable convertible preferred stock, and stockholders' deficit | ||
| Current liabilities: | ||
| Accounts payable | $2,446 | $1,912 |
| Accrued expenses | 14,048 | 9,991 |
| Lease liability - current | 862 | 778 |
| Deferred grant earnings | 1,206 | 3,239 |
| Total current liabilities | 18,562 | 15,920 |
| Lease liability - noncurrent | 5,144 | 5,801 |
| Total long-term liabilities | 5,144 | 5,801 |
| Total liabilities | 23,706 | 21,721 |
| Commitments and contingencies (Note 13) | ||
| Redeemable convertible preferred stock: | ||
| Series D redeemable convertible preferred stock, $0.0001 par value; 391,186,991 and 0 shares authorized at September 30, 2025 and December 31, 2024, respectively; 210,033,285 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively (liquidation preference of $200,000) | 198,870 | — |
| Series C redeemable convertible preferred stock, $0.0001 par value; 147,325,527 and 147,325,537 shares authorized at September 30, 2025 and December 31, 2024, respectively; 147,325,527 shares issued and outstanding at September 30, 2025 and December 31, 2024 (liquidation preference of $225,000) | 224,992 | 224,992 |
| Series B-1 redeemable convertible preferred stock, $0.0001 par value; 4,622,496 shares authorized, issued and outstanding at September 30, 2025 and December 31, 2024 (liquidation preference of $12,000) | 11,981 | 11,981 |
| Series B redeemable convertible preferred stock, $0.0001 par value; 45,010,383 shares authorized, issued and outstanding at September 30, 2025 and December 31, 2024 (liquidation preference of $53,000) | 51,094 | 51,094 |
| Series A-1 redeemable convertible preferred stock, $0.0001 par value; 14,946,844 shares authorized, issued and outstanding at September 30, 2025 and December 31, 2024 (liquidation preference of $16,000) | 15,963 | 15,963 |
| Series A redeemable convertible preferred stock, $0.0001 par value; 5,000,000 shares authorized, issued and outstanding at September 30, 2025 and December 31, 2024 (liquidation preference of $5,000) | 4,793 | 4,793 |
| Stockholders' deficit: | ||
| Common stock, $0.0001 par value; 1,465,092,241 and 325,000,000 authorized at September 30, 2025 and December 31, 2024, respectively; 808,015 and 761,276 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | — | — |
| Additional paid-in-capital | 6,749 | 5,577 |
| Accumulated other comprehensive income | 46 | 163 |
| Accumulated deficit | (280,972) | (199,368) |
| Total stockholders' deficit | (274,177) | (193,628) |
| Total liabilities, redeemable convertible preferred stock, and stockholders' deficit | $257,222 | $136,916 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.